Timothy Rolph - Dec 16, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 06:47 PM
Previous filing
Dec 13, 2022
Next filing
Dec 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +29.1K +50% $0.00 87.2K Dec 16, 2022 Common Stock 29.1K $21.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 29,073 shares underlying such option.